Filing summary
Entity and period: The filing is resTORbio, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed March 12, 2020. This does not match the request’s company name, Adicet Bio, Inc.; it is an annual report, not a standalone Q4 filing. The filing also presents unaudited quarterly results.
Business context and reporting period
resTORbio was a clinical-stage biopharmaceutical company developing RTB101, an oral TORC1 inhibitor intended for aging-related diseases. Its main active program was an early-stage trial in Parkinson’s disease (PD), testing RTB101 alone and with sirolimus. The company had no approved products and generated no product revenue.
Financial performance and liquidity
- Annual results: 2019 revenue was zero. Net loss was $82.7 million, versus $37.6 million in 2018. Research and development expense rose to $73.6 million from $31.1 million; general and administrative expense increased to $11.8 million from $8.6 million. Operating expenses totaled $85.5 million, compared with $39.7 million. With no product revenue, profit margins are not meaningful.
- Q4 results: Unaudited fourth-quarter 2019 operating expenses were $29.4 million and net loss was $28.9 million, versus $6.4 million and $5.8 million, respectively, in Q4 2018. Q4 2019 basic and diluted net loss per share was $0.79, versus $0.21.
- Cash flow: Net cash used in operating activities was $73.7 million in 2019, compared with $35.5 million in 2018. Financing provided $56.4 million in 2019, including approximately $49.7 million net proceeds from an underwritten offering and $6.7 million from at-the-market sales. The filing reports $44.1 million of net cash provided by investing activities, largely reflecting marketable-security maturities and purchases.
- Liquidity and balance sheet: At December 31, 2019, cash and cash equivalents were $33.8 million and marketable securities were $57.7 million, totaling $91.5 million. Current assets were $93.3 million; current liabilities were $12.2 million; total liabilities were $12.2 million. The company reported no credit facility or committed source of additional capital and no debt balance in the presented balance sheet. Management estimated existing funds would support operations at least into 2022, subject to assumptions and execution risks.
- Other: Accumulated deficit was $154.1 million. The company reported $2.8 million of interest income in 2019. It had an effective tax rate of approximately zero and a full valuation allowance against net deferred tax assets.
Material changes versus the prior comparable period
- Annual net loss more than doubled, while operating cash use also increased substantially, primarily amid higher clinical-development spending.
- In November 2019, the Phase 3 PROTECTOR 1 study of RTB101 for prevention of clinically symptomatic respiratory illness in adults 65 and older missed its primary endpoint. The company discontinued development for that indication.
- In December 2019, the company approved a workforce reduction of eight employees, approximately 22% of its workforce at the time. It recorded $0.6 million in restructuring charges; $0.5 million remained accrued at year-end.
- Common shares outstanding increased to 36.4 million at year-end from 28.1 million a year earlier, reflecting 2019 equity offerings and other share activity.
Outlook, commentary, risks and unusual items
- The Phase 1b/2a PD trial tested weekly dosing for four weeks. Interim results reported that the first three regimens were well tolerated and RTB101 was detected in cerebrospinal fluid; sirolimus at 2 mg was not detected there. Full trial data were expected by mid-2020. These are interim findings, not evidence of efficacy.
- Following the PROTECTOR 1 result, management expected research and development and general and administrative spending to decrease substantially, while continuing development focused on RTB101 and PD at a lower expense rate.
- In February 2020, the company engaged JMP Securities to evaluate strategic alternatives, including financing, acquisition, merger, business combination, licensing, or other transactions. There was no assurance of a transaction or changed business plan.
- Management expected continued losses and anticipated needing additional financing. The $50 million at-the-market program had approximately $43 million remaining available at year-end; further equity financing could dilute shareholders.
- Key risks include clinical and regulatory failure, limited cash runway and financing access, reliance on third-party manufacturers and trial providers, dependence on Novartis-licensed intellectual property, competition, and potential delays or disruption from the emerging coronavirus outbreak.
- The Novartis license includes potential clinical, regulatory and commercial milestone payments and tiered royalties. No remaining milestones or royalties were considered reached or probable at year-end. The filing’s descriptions of aggregate clinical milestone amounts are not fully consistent; verify against the executed agreement and notes.
- The independent auditor issued an unqualified opinion on the consolidated financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not opine on internal-control effectiveness.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for resTORbio, not Adicet Bio.
- Review the complete PROTECTOR 1 results and the subsequent status and outcomes of the PD trial; the filing’s PD findings were interim and primarily safety and exposure observations.
- Assess actual cash burn, later financing, and whether management’s runway estimate into 2022 was achieved.
- Check the outcome of the strategic-alternatives review and any resulting transaction, restructuring, or change in operations.
- Verify the Novartis milestone obligations, license status, and any subsequent changes to the company’s share count or financing capacity.